Insmed (INSM) Earnings Date & Reports

Key Takeaways

• Insmed reported third-quarter 2026 total revenue of $524.4 million, up 268% year over year and above the roughly $501 million consensus estimate.
• BRINSUPRI (brensocatib) delivered $400.1 million in quarterly revenue, up 29% sequentially and crossing the $1 billion blockbuster threshold in its first four full quarters of launch.
• ARIKAYCE (amikacin liposome inhalation suspension) generated $124.4 million, up 9% year over year, driven by international growth.
• Net loss was $100.3 million, or $0.46 per share, wider than the consensus loss estimate but a sharp improvement from the $1.75 per-share loss a year earlier.
• Management raised full-year 2026 revenue guidance for both products, and the company launched BRINSUPRI Tablets in Japan during the quarter.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages dedicated to INSM.
• To discover data-driven trading ideas across the market, explore Trending AI Robots.

Earnings Context and Why It Matters

Insmed's third-quarter 2026 report matters because it offers a critical read on whether the company's flagship launch can translate rapid revenue growth into a clearer path toward profitability. BRINSUPRI, a treatment for bronchiectasis, has become the company's growth engine, while the established ARIKAYCE franchise continues to contribute steady revenue. Investors are watching closely to see how operating expenses, research and development (R&D) costs, and gross margins evolve as the commercial portfolio scales. With the stock trading well below its 52-week high entering the print, this report served as a key test of management's ability to reassure the market about sustainable long-term value while managing ongoing net losses.

Reported Results

For the quarter ended September 30, 2026, Insmed reported total revenue of $524.4 million, a 268% increase from $142.3 million in the prior-year period. The figure exceeded the consensus estimate of approximately $501 million. Product revenue was led by BRINSUPRI, which contributed $400.1 million, while ARIKAYCE added $124.4 million.

The company posted a net loss of $100.3 million, or $0.46 per share, compared with a net loss of $370.0 million, or $1.75 per share, in the same quarter last year. The per-share loss came in wider than consensus expectations, reflecting higher operating expenses. R&D expenses rose to $270.0 million from $186.4 million, while selling, general, and administrative expenses increased to $253.0 million from $186.4 million. Despite this, the operating loss narrowed substantially to $89.4 million from $366.0 million a year earlier.

Insmed raised its full-year 2026 guidance for both commercial products. BRINSUPRI revenue guidance was increased to a range of $1.35 billion to $1.4 billion, while ARIKAYCE guidance was raised to $460 million to $470 million. The company reported cash, cash equivalents, and marketable securities of approximately $1.1 billion as of September 30, 2026.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, supporting a more systematic approach to market research. Explore the AI Screener to begin refining your own watchlist.

Market Reaction and Investor Sentiment

Insmed shares rose roughly 13% following the release, as investors responded to the strong revenue beat and the upward revision to full-year guidance. The market's focus centered on BRINSUPRI's continued commercial momentum and the company's expansion into Japan, which management framed as a meaningful growth opportunity not yet reflected in 2026 guidance. At the same time, the wider-than-expected per-share loss and elevated spending drew some scrutiny, with analysts noting that sequential BRINSUPRI growth moderated relative to the launch's earliest quarters. Overall, sentiment leaned positive, with the revenue strength and raised outlook outweighing concerns about near-term profitability.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Insmed can sustain BRINSUPRI's growth trajectory while keeping the spending ramp in check. Management indicated that increased investment in clinical programs and Japan commercial infrastructure during the fourth quarter of 2026 will weigh on near-term cash burn, even as the company targets cash-flow positivity in 2027.

Regulatory and pipeline milestones represent additional catalysts. The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ARIKAYCE in MAC lung disease, with potential label-expansion launches in the U.S. and Japan expected in the first half of 2027 if approved. The company is also advancing its Phase 3 TPIP (treprostinil palmitil inhalation powder) program across multiple large indications.

Key factors to monitor include the pace of BRINSUPRI uptake in Japan, gross-to-net trends across both products, expense discipline, and progress toward the company's stated goal of cash-flow positivity. Management has outlined long-term peak sales expectations exceeding $7 billion for BRINSUPRI and $6 billion for TPIP, but these projections depend on successful clinical and commercial execution over time.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations